IL162293A0 - Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules - Google Patents

Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules

Info

Publication number
IL162293A0
IL162293A0 IL16229302A IL16229302A IL162293A0 IL 162293 A0 IL162293 A0 IL 162293A0 IL 16229302 A IL16229302 A IL 16229302A IL 16229302 A IL16229302 A IL 16229302A IL 162293 A0 IL162293 A0 IL 162293A0
Authority
IL
Israel
Prior art keywords
formulation
dosage form
oral bioavailability
hydrophilic macromolecules
increasing oral
Prior art date
Application number
IL16229302A
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL162293A0 publication Critical patent/IL162293A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
IL16229302A 2001-12-19 2002-12-18 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules IL162293A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34300501P 2001-12-19 2001-12-19
PCT/US2002/041031 WO2003053401A2 (en) 2001-12-19 2002-12-18 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules

Publications (1)

Publication Number Publication Date
IL162293A0 true IL162293A0 (en) 2005-11-20

Family

ID=23344273

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16229302A IL162293A0 (en) 2001-12-19 2002-12-18 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules

Country Status (14)

Country Link
US (1) US20030198619A1 (en)
EP (1) EP1465592A2 (en)
JP (1) JP2005519884A (en)
KR (1) KR20040066177A (en)
CN (1) CN1606432A (en)
AU (1) AU2002359793B2 (en)
CA (1) CA2471096A1 (en)
HU (1) HUP0402451A3 (en)
IL (1) IL162293A0 (en)
MX (1) MXPA04006026A (en)
NO (1) NO20043028L (en)
NZ (1) NZ533060A (en)
WO (1) WO2003053401A2 (en)
ZA (1) ZA200405655B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
CN1678291A (en) * 2002-06-28 2005-10-05 阿尔扎公司 Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050079220A1 (en) * 2003-07-31 2005-04-14 Betty Yu Osmotic engine & dosage form for controlled release of a liquid active agent formulation
JP2007506775A (en) * 2003-09-26 2007-03-22 アルザ・コーポレーシヨン Controlled release formulations exhibiting incremental release rates
WO2005030165A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Dosage form for controlled release of an active agent formulation
EP2184058B1 (en) 2003-09-26 2012-02-08 ALZA Corporation Drug coating providing high drug loading and methods for providing the same
EP1667652B1 (en) * 2003-09-26 2007-05-30 ALZA Corporation Improved controlled release dosage form including a banded engine
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
US7563460B2 (en) * 2004-02-26 2009-07-21 Med Five, Inc. Enteric coated oral pharmaceutical to erode kidney stones
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
RU2393168C2 (en) * 2004-07-19 2010-06-27 Биокон Лимитед Insulin-oligomer conjugates, preparations and use thereof
AR050043A1 (en) 2004-08-03 2006-09-20 Novartis Ag METHODS TO IMPROVE BIODISPONIBILITY AND PHARMACEUTICAL COMPOSITION FOR CARDIOVASCULAR DISORDERS
WO2006023976A2 (en) * 2004-08-23 2006-03-02 Mark Rosenberg Formulations and methods for modulating satiety
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
CN101175488B (en) 2005-05-17 2012-04-18 萨可德公司 Compositions and methods for treatment of eye disorders
RU2437662C2 (en) * 2006-04-07 2011-12-27 Меррион Рисерч Iii Лимитед Solid per oral medication, containing intensifier
JP2009544338A (en) 2006-05-02 2009-12-17 プロテウス バイオメディカル インコーポレイテッド Treatment regimen customized to the patient
SG175681A1 (en) * 2006-10-25 2011-11-28 Proteus Biomedical Inc Controlled activation ingestible identifier
EP1927350A1 (en) * 2006-11-24 2008-06-04 Novartis AG Methods for improving bioavailability of a renin inhibitor
AU2008210291B2 (en) 2007-02-01 2013-10-03 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker systems
MY154556A (en) 2007-02-14 2015-06-30 Proteus Digital Health Inc In-body power source having high surface area electrode
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5808037B2 (en) 2007-10-19 2015-11-10 サーコード バイオサイエンス インク． Compositions and methods for the treatment of diabetic retinopathy
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CA2723558A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730275C (en) 2008-07-08 2019-05-21 Proteus Biomedical, Inc. Ingestible event marker data framework
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI478712B (en) * 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
CA2750158A1 (en) 2009-01-06 2010-07-15 Proteus Biomedical, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US8481067B2 (en) * 2009-06-04 2013-07-09 Clemson University Research Foundation Methods for promoting the revascularization and reenervation of CNS lesions
US8609409B2 (en) 2009-06-04 2013-12-17 Clemson University Methods and compositions for cell culture platform
US8680182B2 (en) 2009-06-04 2014-03-25 Clemson University Research Foundation Methods for promoting the revascularization and reenervation of CNS lesions
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
TWI517050B (en) 2009-11-04 2016-01-11 普羅托斯數位健康公司 System for supply chain management
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2011122523A1 (en) 2010-03-29 2011-10-06 アステラス製薬株式会社 Controlled release pharmaceutical composition
JP5849947B2 (en) 2010-03-29 2016-02-03 アステラス製薬株式会社 Controlled release pharmaceutical composition
TWI557672B (en) 2010-05-19 2016-11-11 波提亞斯數位康健公司 Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
DK2734213T3 (en) * 2011-07-19 2018-08-13 Baxalta GmbH RESORPTION PROMOTERS ADDITIVES TO IMPROVE ORAL FORMULATION OF NON-ANTI-COATING SULPHATE POLYSACCHARIDS
CA2842952C (en) 2011-07-21 2019-01-08 Proteus Digital Health, Inc. Mobile communication device, system, and method
CN110922393A (en) 2012-07-25 2020-03-27 诺华股份有限公司 LFA-1 inhibitors and polymorphs thereof
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3968263A1 (en) 2013-06-04 2022-03-16 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
CN103463290A (en) * 2013-09-10 2013-12-25 南方医科大学 Oral situ gel for preventing and treating gastric ulcer
US9606054B2 (en) * 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
ES2802156T3 (en) * 2014-01-21 2021-01-15 Bpsi Holdings Llc Immediate release film coatings containing medium chain glycerides and substrates coated therewith
CA2949480A1 (en) * 2014-02-24 2015-08-27 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use
US9417181B2 (en) 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
AU2016267264A1 (en) * 2015-05-27 2017-12-07 Vanguard Therapeutics, Inc. Pentosan polysulfate sodium for the treatment of sickle cell disease
CN105131083B (en) * 2015-07-30 2018-07-10 陕西师范大学 Flat almond peptide with angiotensin converting enzyme inhibition activity and preparation method thereof
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
CN105919974B (en) * 2016-04-28 2019-03-01 中国医药集团总公司四川抗菌素工业研究所 Salmon calcitonin phosphatide complexes and its lipid nano particle and preparation method
CN109843149B (en) 2016-07-22 2020-07-07 普罗秋斯数字健康公司 Electromagnetic sensing and detection of ingestible event markers
US20210069237A1 (en) * 2019-09-09 2021-03-11 Harrow Ip, Llc Pharmaceutical compositions comprising heparinoids and methods for preparing thereof
AU2022344774A1 (en) * 2021-09-07 2024-03-14 D&D Pharmatech Inc. Pharmaceutical composition comprising large physiologically active substance and excipient
CN116509794B (en) * 2023-05-19 2024-03-15 上海市肿瘤研究所 Oral thermosensitive gel preparation and preparation method and application thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (en) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
CN1161101C (en) * 1998-12-17 2004-08-11 阿尔扎有限公司 Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
CA2355860C (en) * 1998-12-23 2010-03-30 Alza Corporation Dosage forms comprising porous particles
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US7816398B2 (en) * 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates

Also Published As

Publication number Publication date
JP2005519884A (en) 2005-07-07
WO2003053401A2 (en) 2003-07-03
HUP0402451A3 (en) 2008-04-28
CN1606432A (en) 2005-04-13
CA2471096A1 (en) 2003-07-03
AU2002359793B2 (en) 2007-06-14
WO2003053401A3 (en) 2004-01-15
EP1465592A2 (en) 2004-10-13
KR20040066177A (en) 2004-07-23
HUP0402451A2 (en) 2005-07-28
NZ533060A (en) 2006-03-31
NO20043028L (en) 2004-09-20
ZA200405655B (en) 2005-08-15
MXPA04006026A (en) 2005-03-31
US20030198619A1 (en) 2003-10-23
AU2002359793A1 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
HUP0402451A3 (en) Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
HUP0303800A3 (en) Pharmaceuticals and dosage forms of epothilones for oral administration
PL356358A1 (en) Solid dosage form of someticone for oral administration
IL166489A (en) Two-layerd oral dosage form for once-a-day administration of paliperidone and uses thereof
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1383518A4 (en) Oral delivery of macromolecules
HUP0400281A3 (en) Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
HK1070285A1 (en) Pharmaceutical dosage form of amorphous nelfinavirmesylate
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
HK1072898A1 (en) Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
PL364621A1 (en) Nicotine-containing oral dosage form
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
IL162666A0 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
HUP0500638A3 (en) Flashmelt oral dosage formulation
HUP0400386A3 (en) Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions
IL154268A0 (en) Improved solid pharmaceutical dosage formulation of hydrophobic drugs
IL162510A0 (en) Pharmaceutical suspension for oral administration
AU2002317063A (en) Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
AU2002317063A1 (en) Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
IL165510A0 (en) An amorphous form of levocetirizine dihydrochloride pharmaceutical compositions containing the same and processes for the preparation thereof
IL155855A0 (en) Pharmaceutical formulation of gepirone for oral administration
EP1361866A4 (en) Emulsions as solid dosage forms for oral administration
HUP0401371A3 (en) Pharmaceutical formulation containing an ltb4 antagonist and process for its preparation